Hoda Daanish, Perez Domingo G, Loprinzi Charles L
Mayo Clinic, Rochester, Minnesota 55905, USA.
Breast J. 2003 Sep-Oct;9(5):431-8. doi: 10.1046/j.1524-4741.2003.09526.x.
Hot flashes can be a major problem for patients with a history of breast cancer. The precipitation of menopause in premenopausal women who undergo chemotherapy for breast cancer can lead to the rapid onset of hot flash symptoms that are more frequent and more severe than those associated with natural menopause. In addition, tamoxifen, historically the most commonly prescribed pharmacologic agent for the treatment of breast cancer, is associated with hot flashes in more than 50% of its users. Although estrogen relieves hot flashes in 80-90% of women who initiate treatment, its use in women with a history of breast cancer is controversial, and most physicians in the community will not use this treatment modality. In addition, the results of the long-awaited Women's Health Initiative study and other recent studies suggest that long-term estrogen therapy should not be recommended for most women for a variety of reasons. However, hot flashes in breast cancer survivors should no longer be considered untreatable, as there are many pharmacologic and nonpharmacologic treatments that can help alleviate this problem. This article reviews the current strategies for the management of hot flashes in breast cancer survivors and the evidence supporting their use.
潮热对于有乳腺癌病史的患者而言可能是一个主要问题。接受乳腺癌化疗的绝经前女性出现绝经，会导致潮热症状迅速发作，且比自然绝经相关的潮热症状更频繁、更严重。此外，他莫昔芬是历来治疗乳腺癌最常用的药物，超过50%的使用者会出现潮热症状。虽然雌激素能缓解80%至90%开始接受治疗的女性的潮热症状，但其在有乳腺癌病史女性中的使用存在争议，该领域的大多数医生不会采用这种治疗方式。此外，期待已久的女性健康倡议研究及其他近期研究结果表明，出于多种原因，大多数女性不应接受长期雌激素治疗。然而，乳腺癌幸存者的潮热不应再被视为无法治疗，因为有许多药物和非药物治疗方法有助于缓解这一问题。本文综述了目前乳腺癌幸存者潮热管理策略及其使用依据。
